Immunovant (IMVT) EV to EBITDA (2019 - 2026)
Powered by 
Analysis
Immunovant (IMVT) EV to EBITDA (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Immunovant | 8.13 Bn | 8.13 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -46.66 |
| Mar 31, 2026 | -27.63 |
| Dec 31, 2025 | -38.26 |
| Sep 30, 2025 | -18.20 |
| Jun 30, 2025 | -17.86 |
| Mar 31, 2025 | -20.72 |
| Dec 31, 2024 | -29.48 |
| Sep 30, 2024 | -33.98 |
| Jun 30, 2024 | -37.89 |
| Mar 31, 2024 | -54.18 |
| Dec 31, 2023 | -105.23 |
| Sep 30, 2023 | -82.05 |
| Jun 30, 2023 | -29.03 |
| Mar 31, 2023 | -27.22 |
| Dec 31, 2022 | -29.63 |
| Sep 30, 2022 | -5.14 |
| Jun 30, 2022 | -0.68 |
| Mar 31, 2022 | -3.14 |
| Dec 31, 2021 | -10.96 |
| Sep 30, 2021 | -11.67 |